See every side of every news story
Published loading...Updated

CuraSen treats first subject in neurogenic orthostatic hypotension trial

Summary by Clinical Trials Arena
CuraSen Therapeutics has treated the first subject in the Phase I trial of CuraAX to treat neurogenic orthostatic hypotension (nOH).The post CuraSen treats first subject in neurogenic orthostatic hypotension trial appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)